Developing breakthrough AXL therapeutics to improve patients' lives

Developing breakthrough AXL therapeutics to improve patients' lives
Learn About Us
Background
DecorationDecoration

Information about the Warrants

Read more
Old woman

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections

Recent News

BerGenBio ASA: Final results for the last exercise period for warrants issued in connection with rights issue

Read more

BerGenBio ASA: Mandatory notification of trade by primary insiders and close associates

Read more

BerGenBio ASA: Last day of the last exercise period for warrants issued in connection with rights issue

Read more

BerGenBio ASA: Last day of trading in warrants

Read more

BerGenBio ASA: Information about the last exercise period for Warrants issued in connection with rights issue

Read more

BerGenBio ASA: Commencement of the last exercise period for warrants issued in connection with rights issue

Read more

BerGenBio ASA secures underwriting of NOK 118 million gross proceeds representing minimum 80% exercise of the remaining Warrants, providing funding into 2H 2025

Read more

BerGenBio ASA: Exercise price in the last exercise period for warrants issued in connection with rights issue

Read more

BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation

Read more
All news